“`html
WHO Issues First Guideline on GLP-1 Therapies for Obesity
Table of Contents
The World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies to treat obesity, recognizing it as a chronic, relapsing disease. This comes as obesity affects over 1 billion people globally and was linked to 3.7 million deaths in 2024. Without intervention, obesity rates are projected to double by 2030.
Understanding the Obesity Crisis
Obesity isn’t simply a matter of lifestyle; it’s a complex chronic disease. it significantly increases the risk of serious health problems, including cardiovascular diseases, type 2 diabetes, and certain cancers. The WHO’s response highlights a shift towards recognizing obesity as a medical condition requiring complete treatment, not just individual willpower.
What are GLP-1 Therapies?
GLP-1 therapies are a class of medications originally developed to treat type 2 diabetes. They work by mimicking the effects of the naturally occurring hormone GLP-1, which plays a role in regulating blood sugar and appetite. Specifically, they:
- Increase insulin release: Helping the body use glucose more effectively.
- Suppress glucagon secretion: Reducing the liver’s production of glucose.
- Slow gastric emptying: Making you feel fuller for longer.
- Reduce appetite: Leading to decreased food intake.
Because of these effects, GLP-1 therapies have been found to promote weight loss in individuals with obesity, even those without diabetes.
WHO’s New Recommendations
In September 2025, the WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups. the new guideline expands on this, offering conditional recommendations for using these therapies as part of a broader obesity treatment plan. This means the WHO acknowledges the potential benefit of GLP-1s, but emphasizes they should be used in conjunction with:
- Healthy diets: Focusing on nutrient-rich foods and portion control.
- Regular physical activity: Aiming for at least 150 minutes of moderate-intensity exercise per week.
- Support from health professionals: Including doctors, dietitians, and therapists.
The WHO stresses that medication is not a standalone solution. It’s a tool to support lifestyle changes and provide a more effective path to weight management.
Why This Matters: A Shift in Viewpoint
this guideline represents a significant shift in how the global health community views obesity.For years, it was frequently enough framed as a personal failing. The WHO’s stance acknowledges the biological and environmental factors that contribute to obesity, and the need for medical intervention in some cases.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, stated, “Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care.” This statement underscores the importance of long-term management and support for individuals living with obesity.
Key Takeaways
- Obesity is a global health crisis affecting over 1 billion people.
- GLP-1 therapies can be a valuable tool in managing obesity, but are most effective when combined with lifestyle changes.
- The WHO recognizes obesity as a chronic disease requiring comprehensive, lifelong care.
- These therapies were added to the Essential Medicines List for both type 2 diabetes and obesity.
Frequently Asked Questions (FAQ)
Q: Are GLP-1 therapies suitable for everyone
Worth a look